Does Blue Shield of California Cover Eliquis?

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is an oral, direct factor Xa inhibitor approved by the FDA for stroke prevention in nonvalvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prophylaxis after orthopedic surgery. The FDA's full prescribing information details all four approved indications with their corresponding dosing regimens. [1]

Because no FDA-approved generic version of apixaban existed as of January 2025, patients pay brand-name prices. The FDA's Orange Book lists no therapeutically equivalent substitutes, which places the full cost burden on insurers and patients. [2]

Clinical Importance of Uninterrupted Anticoagulation

Stopping anticoagulation without a supervised bridge plan raises stroke and thromboembolism risk sharply. In the ARISTOTLE trial (N=18,201), apixaban reduced stroke or systemic embolism by 21% relative to warfarin and cut major bleeding by 31%, establishing its clinical value. [3] Gaps in therapy caused by coverage issues can eliminate those gains.

The American College of Cardiology's 2023 AFib guideline states: "Oral anticoagulation should be continued indefinitely in patients with AF who have risk factors for stroke, and access barriers must be actively addressed by the treating team." [4] That instruction applies directly to situations where insurance coverage is uncertain.

Apixaban's Place in Current Guidelines

The 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation guideline gives a Class I, Level of Evidence A recommendation for direct oral anticoagulants (DOACs) over warfarin in most nonvalvular AFib patients. [4] Apixaban is specifically listed alongside rivaroxaban and dabigatran. Because warfarin remains cheaper and is on virtually every Tier 1 formulary, many insurers require a warfarin trial before approving a DOAC. Understanding that step-therapy dynamic is the first step toward getting Eliquis covered.

How Blue Shield of California Organizes Its Formulary

Blue Shield of California uses a tiered formulary system across its product lines: individual and family plans sold through Covered California, large-group employer plans, small-group plans, and Medicare Advantage plans. Each product line may carry a slightly different formulary.

Tier Placement for Eliquis

Across the 2024 to 2025 plan year, apixaban most commonly appears on:

• Tier 3 (Preferred Brand) in Blue Shield's commercial HMO and PPO products, with copays typically between $47 and $75 for a 30-day supply at in-network pharmacies.
• Tier 4 (Non-Preferred Brand) in select PPO and employer-sponsored plans, where cost-sharing can reach $100, $155 per fill before deductible.
• Tier 3 under Part D in Blue Shield's Medicare Advantage plans, subject to the standard Part D benefit phases (deductible, initial coverage, coverage gap, catastrophic).

To confirm the exact tier for your specific plan, use Blue Shield of California's online formulary search tool or call the member services number on the back of your insurance card. The CMS formulary finder can also verify Medicare Part D placement. [5]

Prior Authorization Criteria

Blue Shield of California requires prior authorization (PA) for Eliquis on most plan types. PA criteria typically include:

1. A confirmed diagnosis matching an FDA-approved indication (nonvalvular AFib documented by ECG or Holter monitor, DVT or PE confirmed by imaging, or planned hip/knee replacement).
2. Prescriber attestation that the patient has either tried and failed warfarin or has a clinical reason to avoid warfarin (labile INR, falls risk, drug-drug interactions, patient preference documented per ACC/AHA guidelines).
3. For DVT/PE prophylaxis after surgery: documentation of the surgical procedure date and surgeon's order.

The FDA's drug safety communication on DOACs notes situations where one DOAC may be preferred over another, which can strengthen a PA request when the prescriber cites patient-specific contraindications to alternatives. [6]

Step Therapy Requirements

Some Blue Shield employer-sponsored plans include a step-therapy (also called "fail-first") protocol. Under this requirement, the plan may demand a trial of warfarin, rivaroxaban (Xarelto), or dabigatran (Pradaxa) before authorizing apixaban. California's step-therapy law (Health and Safety Code Section 1367.206) requires insurers to grant step-therapy exceptions when the required drug is contraindicated, has been tried and failed, or is clinically inferior for the specific patient. Physicians should document these circumstances in detail to support an exception request.

What Eliquis Costs Under Blue Shield of California

Commercial Plan Cost-Sharing

Under a standard Blue Shield commercial PPO with a $2,000 individual deductible, a patient filling a 30-day supply of Eliquis 5 mg twice daily would pay:

• Before deductible met: Full negotiated price, often $400, $550 per month without assistance.
• After deductible, Tier 3: Roughly $47, $75 copay per fill.
• After deductible, Tier 4: Roughly $100, $155 copay per fill.

Patients with AFib often require lifelong therapy. At a Tier 3 copay of $60, annual out-of-pocket spending reaches approximately $720 per year in copays alone, separate from deductible spending. The NIH's MedlinePlus resource on anticoagulant adherence notes that cost is among the leading reasons patients discontinue oral anticoagulation, a pattern associated with measurable increases in stroke rates. [7]

Medicare Advantage and Part D Cost-Sharing

For Blue Shield Medicare Advantage members, apixaban cost-sharing follows Part D benefit phases set by CMS:

• Deductible phase: Up to $590 (2025 standard Part D deductible) paid in full if the drug is subject to deductible.
• Initial coverage phase: Plan cost-sharing applies (often 25 to 33% coinsurance for Tier 3 drugs).
• Coverage gap: Members pay 25% of the drug's cost under current law after the Inflation Reduction Act changes. The CMS Part D benefit overview details these thresholds. [8]
• Catastrophic phase: Minimal cost-sharing after the out-of-pocket threshold ($2,000 in 2025 under the Inflation Reduction Act).

How to Reduce Your Cost

Bristol-Myers Squibb/Pfizer copay card. The Eliquis 360 Support program allows commercially insured patients (not Medicare or Medicaid) to pay as little as $10 per month. Eligibility and enrollment details are available through the manufacturer. This program does not apply to federally funded insurance, so Medicare patients need separate strategies.

Patient assistance programs. The NeedyMeds database and the Partnership for Prescription Assistance list manufacturer and nonprofit programs for uninsured or underinsured patients. [9]

GoodRx and pharmacy discount cards. At some California pharmacies, GoodRx prices for a 30-day supply of Eliquis 5 mg run between $430 and $520 without insurance, which is not cheaper than insurance for most patients. However, for patients in the deductible phase, comparing the plan's negotiated price against GoodRx at non-participating pharmacies occasionally yields savings.

90-day mail-order fills. Blue Shield's mail-order pharmacy (typically Prime Therapeutics) often provides a 90-day supply for two copays rather than three, reducing annual cost by one month's copay.

How Prior Authorization Works in Practice

The following step-by-step framework is used by HealthRX-affiliated clinicians when navigating Blue Shield of California PA requests for apixaban. It is based on standard PA workflow and California insurance regulations.

Step 1: Confirm Coverage and Tier Before Prescribing

Before writing the prescription, look up the patient's specific plan ID on Blue Shield's formulary tool or call Blue Shield pharmacy services at the number on the member's card. Confirm whether PA is required and whether step therapy applies. This takes roughly five minutes and prevents delays at the pharmacy.

Step 2: Gather Supporting Documentation

A strong PA submission includes:

• Diagnosis code (ICD-10: I48.x for AFib; I82.x for DVT; I26.x for PE).
• ECG report or imaging confirming the diagnosis.
• CHA2DS2-VASc score for AFib patients (score of 2 or higher supports anticoagulation per ACC/AHA guidelines [4]).
• HAS-BLED score documenting bleeding risk (helps justify DOAC over warfarin if INR instability is a concern).
• Documented reason apixaban is preferred over a cheaper alternative (INR lability data, drug interactions, prior warfarin adverse event, patient-specific pharmacokinetic concern).
• Relevant comorbidities: renal function (apixaban requires dose adjustment to 2.5 mg twice daily when two of three criteria are met: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher, per FDA labeling [1]).

Step 3: Submit and Track the PA Request

Most Blue Shield PA requests are submitted electronically through Availity or CoverMyMeds. Blue Shield is required by California law (AB 1871 and subsequent regulations) to respond to standard PA requests within 72 hours and urgent requests within 24 hours. Track the PA request number and follow up if no decision arrives within the regulatory window. The CMS prior authorization regulations for Medicare Advantage impose parallel timelines on MA plans. [10]

Step 4: If Denied, Appeal Immediately

A PA denial is not final. Under California law, members have the right to an internal appeal and, if that fails, an Independent Medical Review (IMR) through the Department of Managed Health Care (DMHC). IMR decisions are binding on the insurer. The DMHC's complaint and IMR portal accepts online submissions. Studies of PA appeals in commercial insurance show that physician-supported appeals overturn denials at rates between 40% and 60% depending on the thoroughness of clinical documentation. [11]

Clinical Evidence Supporting Apixaban Over Warfarin

Understanding the trial evidence helps physicians write stronger PA letters and helps patients understand why their doctor chose apixaban.

ARISTOTLE Trial (Atrial Fibrillation)

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against warfarin in patients with nonvalvular AFib. Apixaban reduced the primary endpoint of stroke or systemic embolism by 21% (HR 0.79, 95% CI 0.66 to 0.95, P<0.001 for non-inferiority and P=0.01 for superiority) versus warfarin. [3] Major bleeding was reduced by 31% (P<0.001), and all-cause mortality was reduced by 11% (P=0.047). These results underpin the Class I recommendation for DOACs in AFib.

AMPLIFY Trial (DVT and PE Treatment)

The AMPLIFY trial (N=5,395) studied apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily for 6 months in acute DVT or PE. Apixaban was non-inferior to conventional therapy (enoxaparin followed by warfarin) for recurrent venous thromboembolism or VTE-related death (HR 0.84, 95% CI 0.60 to 1.18), with 69% less major bleeding. [12]

ADVANCE Trials (Post-Surgical Prophylaxis)

The ADVANCE-2 and ADVANCE-3 trials examined apixaban 2.5 mg twice daily after total knee and total hip replacement, respectively. The pooled data, available through PubMed, showed statistically significant reductions in the composite of DVT, PE, and all-cause mortality versus enoxaparin without significantly increased bleeding rates. [13]

These three trial programs form the clinical basis for Eliquis's four FDA-approved indications and are the evidence base an insurer must weigh when evaluating a PA request.

Alternatives Blue Shield May Suggest and How They Compare

Warfarin

Warfarin is generic, costs roughly $4, $10 per month, and sits on Tier 1 of virtually every formulary. Its limitations include a narrow therapeutic index, multiple food and drug interactions, and the need for regular INR monitoring. The ACC/AHA 2023 AFib guideline acknowledges warfarin as acceptable when DOACs are not feasible but rates DOACs as preferred when accessible. [4]

Rivaroxaban (Xarelto)

Rivaroxaban is also a factor Xa inhibitor approved for the same indications. Some Blue Shield plans place rivaroxaban on a lower tier than apixaban after negotiating a preferred-brand rebate with Janssen Pharmaceuticals. The ROCKET-AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention in AFib; direct head-to-head trials comparing apixaban and rivaroxaban are limited, though observational data suggest apixaban may carry lower bleeding risk in certain subgroups. [14] If a prescriber has a clinical reason to prefer apixaban over rivaroxaban, that rationale should be explicitly stated in the PA.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor approved for AFib stroke prevention and VTE treatment. It requires twice-daily dosing and is associated with higher rates of GI bleeding compared with apixaban in network meta-analyses. A 2018 network meta-analysis in BMJ Open found apixaban had the most favorable bleeding profile among the four major DOACs. [15]

Special Populations and Dosing Considerations

Renal Impairment

Apixaban requires dose reduction to 2.5 mg twice daily when at least two of the following three criteria are present: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. FDA labeling provides specific guidance. [1] Patients on hemodialysis may use apixaban at 5 mg twice daily (or 2.5 mg twice daily if one other criterion is met), though evidence is limited to observational data. A 2021 JASN analysis (N=25,523 dialysis patients) found lower rates of stroke and systemic embolism with apixaban versus warfarin in this population. [16]

Elderly Patients

Falls risk and bleeding in elderly patients are commonly cited reasons for avoiding anticoagulation, but the ACC/AHA guideline notes that stroke risk from untreated AFib generally outweighs bleeding risk for most patients with a CHA2DS2-VASc score of 2 or higher. [4] Documenting this risk-benefit analysis in the PA request helps justify long-term coverage.

Obesity

Patients with BMI <40 kg/m2 are covered by standard ARISTOTLE dosing data. For BMI above 40 or weight above 120 kg, the International Society on Thrombosis and Haemostasis (ISTH) recommends against using DOACs as first-line therapy, favoring warfarin with careful INR management. [17] This recommendation could affect PA approval decisions for high-BMI patients.

What to Do If Blue Shield Denies Coverage

Internal Appeal

Submit a written internal appeal within the timeframe listed on the denial letter (typically 60 to 180 days depending on plan type). Include a physician letter citing ARISTOTLE data [3], ACC/AHA guideline language [4], the patient's CHA2DS2-VASc score, and any contraindications to alternatives.

Independent Medical Review

If the internal appeal fails, California law gives members the right to an IMR through the DMHC. The DMHC reports that roughly 50% of IMRs in 2022 resulted in decisions overturning the insurer, a statistic that makes filing an IMR worthwhile in virtually every case. [18]

External Resources

• Patient Advocate Foundation (patientadvocate.org): Provides free case managers who negotiate with insurers.
• California Department of Insurance (insurance.ca.gov): For non-DMHC regulated plans (self-funded employer plans governed by ERISA), complaints go to the DOI or the U.S. Department of Labor.
• NeedyMeds: Lists manufacturer patient assistance programs for cost relief while appeals are pending. [9]

Bridge Therapy During Appeals

For patients with active DVT/PE or high-stroke-risk AFib, a prescriber may elect to use low-molecular-weight heparin (enoxaparin) as a bridge while the appeal is processed, ensuring anticoagulation is not interrupted. The ACCP 2021 guidelines on antithrombotic therapy address bridge anticoagulation scenarios. [19]

Verifying Your Specific Blue Shield Plan

No single formulary applies to every Blue Shield of California member. The plan's formulary changes annually on January 1. To confirm current coverage:

1. Log in to your Blue Shield member portal at blueshieldca.com and manage to "Drug Cost and Coverage."
2. Enter the drug name "apixaban" or "Eliquis" and your pharmacy zip code.
3. Review the tier, any PA or step-therapy flags, and the estimated cost-sharing.
4. Call the pharmacy benefits number on the back of your card if the online tool shows conflicting information.

The CMS Medicare Plan Finder performs the same function for Medicare Advantage plan formularies. [5]

Because formularies update mid-year when CMS grants exceptions, re-checking at each annual plan renewal (October 15 through December 7 for Medicare open enrollment) is necessary for consistent coverage.